COVID-19 疫苗在血液恶性肿瘤患者中的有效性。
COVID-19 vaccine effectiveness in patients with hematologic malignancy.
机构信息
Mays Cancer Center at UTHealth San Antonio MD Anderson, San Antonio, Texas, USA.
Tempus Labs, Chicago, Illinois, USA.
出版信息
Transpl Infect Dis. 2022 Dec;24(6):e13850. doi: 10.1111/tid.13850. Epub 2022 Aug 16.
Abstract
COVID‐19 vaccine response → HM<solid. Breakthrough infections → HM>solid. Vaccine effectiveness → Population studies urgently needed. Early #COVID19CP could be lifesaving in immunocompromised HM pts. This article is protected by copyright. All rights reserved
摘要
新冠病毒疫苗反应→HM<实线.突破性感染→HM>实线.疫苗有效性→迫切需要进行人群研究。早期#COVID19CP 在免疫功能低下的 HM 患者中可能具有救生作用。本文受版权保护。版权所有。
相似文献
1
COVID-19 vaccine effectiveness in patients with hematologic malignancy.
Transpl Infect Dis. 2022 Dec;24(6):e13850. doi: 10.1111/tid.13850. Epub 2022 Aug 16.
2
SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.
Oncologist. 2022 Nov 3;27(11):e917-e918. doi: 10.1093/oncolo/oyac173.
3
COVID-19 in patients with hematologic malignancy.
Blood. 2022 Jul 21;140(3):236-252. doi: 10.1182/blood.2021012251.
4
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
5
COVID-19 vaccines for patients with haematological conditions.
Lancet Haematol. 2021 May;8(5):e312-e314. doi: 10.1016/S2352-3026(21)00073-9. Epub 2021 Mar 31.
6
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Oncologist. 2022 Apr 5;27(4):e357-e361. doi: 10.1093/oncolo/oyac032.
7
Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
Lancet Haematol. 2021 Aug;8(8):e540-e542. doi: 10.1016/S2352-3026(21)00197-6. Epub 2021 Jul 2.
8
COVID-19 vaccine response in patients with hematologic malignancy: A systematic review and meta-analysis.
Am J Hematol. 2022 Apr;97(4):E132-E135. doi: 10.1002/ajh.26459. Epub 2022 Jan 13.
9
Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.
Cancer Control. 2022 Jan-Dec;29:10732748211070720. doi: 10.1177/10732748211070720.
10
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
Am J Hematol. 2021 Oct 1;96(10):1195-1203. doi: 10.1002/ajh.26284. Epub 2021 Jul 14.
引用本文的文献
1
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders.
Best Pract Res Clin Haematol. 2022 Sep;35(3):101375. doi: 10.1016/j.beha.2022.101375. Epub 2022 Aug 24.
Zotero 插件